Brief: Repare Therapeutics Rp-1664 Demonstrated Potent & Selective Inhibition Of Plk4, Synthetic Lethality In Trim37-High Tumor Cells In Preclinical Studies
15/11/2023 12:08
Nov 15 (Reuters) - Repare Therapeutics Inc RPTX.O :
* REPARE THERAPEUTICS: RP-1664 DEMONSTRATED POTENT &
SELECTIVE
INHIBITION OF PLK4, SYNTHETIC LETHALITY IN TRIM37-HIGH TUMOR
CELLS IN PRECLINICAL STUDIES
* REPARE THERAPEUTICS INC: RP-3467 DEMONSTRATED COMPLETE,
SUSTAINED REGRESSIONS PRECLINICALLY IN COMBINATION WITH PARPI
* REPARE THERAPEUTICS INC: RP-3467 DEMONSTRATED COMPELLING
ANTI-TUMOR ACTIVITY IN COMBINATION WITH RADIOLIGAND THERAPY
(RLT) AND CHEMOTHERAPY
* REPARE THERAPEUTICS INC: EXPECTS TO INITIATE CLINICAL
TRIALS OF
RP-1664 IN 1H 2024 AND RP-3467 IN 2H 2024
Source text for Eikon: ID:nBw4tJFJna
Further company coverage: RPTX.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Repare Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Repare Therapeutics Announces Acquisition Of Polθ ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration
Brief: Repare Signs Support Agreements With Key Shareholders For Xenotherapeutics Deal
Repare Therapeutics Q2 net loss narrows to $16.7 mln